Why Now Is the Right Time to Build a Retatrutide Program — and Why MedClinic Partners Is the Right Partner

The window for building a first-mover retatrutide program is open today. It will not be open indefinitely. FDA approval — likely within 18–36 months — will change the market fundamentally. The practices that use this window to build clinical experience, patient relationships, and operational infrastructure will be positioned to win in the post-approval market. The practices that wait will be starting from scratch in a crowded field.

The clinical data is compelling. The TRIUMPH Phase 3 trial data is not preliminary — it is robust, peer-reviewed evidence showing weight loss outcomes that are meaningfully superior to every currently approved GLP compound. The clinical case for retatrutide is established.

The compliance pathway exists. The IRB framework that authorizes compliant engagement with retatrutide is well-established. Independent IRBs that serve private practice investigators have reviewed and approved retatrutide research protocols. The pathway is not theoretical — it is operational.

The market is ready. The GLP market has created a large population of patients who have been on semaglutide or tirzepatide and have not achieved their goals. These patients are motivated, engaged, and actively looking for a more potent option. They are the ideal candidates for a retatrutide research program.

The competitive landscape is still limited. Most practices in most markets have not built compliant retatrutide programs. The practices that move now will have a meaningful head start before the market becomes crowded.

FDA approval will change everything. When branded retatrutide is commercially available, the IRB pathway becomes less necessary, the market opens up to every prescriber, and the first-mover advantage erodes. The practices that have been running compliant programs for 18–24 months before approval will have a significant advantage — but that advantage requires starting now.

The practices that wait for approval to start thinking about retatrutide will be starting from scratch in a market where the early movers have already established patient relationships, clinical expertise, and operational infrastructure.

MedClinic Partners was built for this moment. We are the only platform that integrates 503A and 503B compounded GLPs, research-grade peptides including retatrutide, and the compliance infrastructure to support a defensible research program — all through one portal, with no portal fees.

What we provide for retatrutide programs:

• Research-grade retatrutide with independent third-party COAs covering identity, purity, potency, sterility, and endotoxin testing
• Cold chain shipping Monday through Thursday with next-day delivery for orders placed by 5 PM
• Full supply chain documentation designed to support IRB audit, medical board review, and M&A due diligence
• NPI-verified provider portal with 24/7 access
• A team that understands the compliance requirements and can discuss supply arrangements tailored to your program's needs

What we do not provide:

We are not healthcare counsel. We are not an IRB. We do not provide legal advice or medical advice. For the legal and IRB components of your program, you need qualified healthcare counsel and an independent IRB. We can discuss the supply chain and documentation components — and we can connect you with resources for the other components.

If you are ready to explore building a retatrutide research program, the next step is portal access. The onboarding process takes minutes. NPI verification is automatic through the CMS registry. Once you have portal access, you can review our product catalog, our quality documentation standards, and our supply arrangements.

The window is open. The clinical data is compelling. The compliance pathway exists. The market is ready. The question is whether you are going to build the program that your patients need — and that your practice deserves.